Companies › Stelexis BioSciences
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eganelisib PI3-kinase p110-gamma subunit inhibitor | PIK3CG | Phase 1 | AML, Adult; Leukemia, Myeloid | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06533761 | Eganelisib | Phase 1 | AML, Adult | Oncology | Dec 2027 |
| NCT07439211 | Eganelisib | Phase 1 | Leukemia, Myeloid | Oncology | Feb 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.